Advertisement

© 1972

International Symposium on Adriamycin

Milan, 9th-10th September, 1971

  • Stephen K. Carter
  • A. Di Marco
  • M. Ghione
  • I. H. Krakoff
  • G. Mathé
Conference proceedings

Table of contents

  1. Front Matter
    Pages I-VIII
  2. Short Summary of the Informal Meeting Preceeding the Adriamycin Symposium

    1. Stephen K. Carter, A. Di Marco, M. Ghione, I. H. Krakoff, G. Mathé
      Pages 1-7
  3. Chemistry of Adriamycin

    1. Front Matter
      Pages 9-9
    2. F. Arcamone, G. Cassinelli, G. Franceschi, S. Penco, C. Pol, S. Redaelli et al.
      Pages 9-22
  4. Activity at Cell Level

  5. Activity against Experimental Tumors

  6. Pharmacology and Pharmacokinetics

    1. Front Matter
      Pages 96-96
    2. E. Arena, N. D’Alessandro, L. Dusonchet, N. Gebbia, F. Gerbasi, R. Sanguedolce et al.
      Pages 96-116
    3. D. W. Yesair, M. A. Asbell, R. Bruni, F. J. Bullock, E. Schwartzbach
      Pages 117-123
    4. Kiyoji Kimura, Hiroshi Fujita, Yasunobu Sakai
      Pages 124-134
  7. Clinical Activity and Side Effects

    1. Front Matter
      Pages 135-135
    2. H. Begemann, G. Wernekke
      Pages 135-138

About these proceedings

Introduction

The impressive advances in all branches of medical science during the first half of this century with the discovery of many chemotherapeutic or immunogenic agents gave rise to brilliant achievements in the struggle against some infectious diseases and aroused in many scientists the wishful thought that drugs for cancer therapy would, soon lead to additional great success. Notwithstanding ever-increasing worldwide endeavors, the major problems in prevention or treatment of neoplastic diseases are still unsolved. The approach to the resolution of these problems follows many different pathways. Basic research tries to cast light on the genetic and biochemical processes underly­ ing cell division and differentiation as well as the interactions occurring between the cell and the oncogenic stimulus, or between the neoplastic cells and the different body systems endowed with immunological reactivity. Another line of approach, coherent with the classic basis of chemotherapy, relies upon the search for new compounds selectively blocking the multiplication of the neoplastic cells. The remarkable progress made in treating human cancer, as a result of these efforts, has been until now ascribable chiefly to the accomplishment of the chemo­ therapeutic approach. Studies on the cytostatic activity of the anthracycline antibiotics carried out over many years eventually led the investigators of Farmitalia (Milan, Italy) to discover and characterize some new compounds endowed with interesting chemotherapeutic properties against malignant neoplastic diseases.

Keywords

antibiotics cancer cancer therapy cell chemotherapy diseases infectious disease lead research therapy

Editors and affiliations

  • Stephen K. Carter
    • 1
  • A. Di Marco
    • 2
  • M. Ghione
    • 3
  • I. H. Krakoff
    • 4
  • G. Mathé
    • 5
  1. 1.Chief Cancer Therapy Evaluation Branch National Cancer InstituteBethesdaUSA
  2. 2.National Cancer InstituteMilanItaly
  3. 3.Chief, Medical Research FarmitaliaMilanItaly
  4. 4.Sloan Kettering Institute for Cancer ResearchNew YorkUSA
  5. 5.Institut de Cancérologie et d’ImmunogénétiqueVillejuifFrance

Bibliographic information

  • Book Title International Symposium on Adriamycin
  • Book Subtitle Milan, 9th-10th September, 1971
  • Editors Stephen K. Carter
    A. Di Marco
    M. Ghione
    I.H. Krakoff
    G. Mathe
  • DOI https://doi.org/10.1007/978-3-642-95227-2
  • Copyright Information Springer-Verlag Berlin Heidelberg 1972
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Hardcover ISBN 978-3-540-05890-8
  • Softcover ISBN 978-3-642-95229-6
  • eBook ISBN 978-3-642-95227-2
  • Edition Number 1
  • Number of Pages VIII, 252
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Pharmacology/Toxicology
    Medicine/Public Health, general
  • Buy this book on publisher's site
Industry Sectors
Biomedicine
Pharma
Health & Hospitals
Biotechnology
Pharmacology & Toxicology
Law
Consumer Packaged Goods